

December 8, 2015  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President & Chief Executive Officer

## **Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients**

TOKYO, Japan, December 8, 2015 --- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, “Symbio”) announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, “Onconova”) has presented the results of its clinical trial for oral rigosertib in combination with azacitidine for the treatment of front-line and second-line higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML), referred to as the 09-08 trial, at the 57th ASH Meeting. According to Onconova, combination results were positive, achieving a 77% overall response rate.

For more details on this press release, please visit Onconova’s homepage at <http://investor.onconova.com/releases.cfm>

Symbio has already started the Phase 1 clinical trial in Japan for oral rigosertib (SyB C-1101, oral formulation) combined with azacitidine in HR-MDS patients (“Phase I Combination Trial”) in December 2015 and upon completion of this Phase 1 Combination Trial, Symbio will consider participating in a global Phase 3 trial which Onconova plans to initiate.

### **[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

### **About Myelodysplastic Syndromes (MDS)**

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in number of red blood cells), with a high rate of progression to AML. There are an estimated 11,000 MDS patients in Japan alone, with the number of cases expected to increase as the population ages. MDS and AML are widely recognized as blood

disorders that are difficult to manage given the limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower-risk MDS and HR-MDS.

**About Azacitidine (Vidaza: currently marketed by Nippon Shinyaku Co., Ltd.)**

Vidaza was approved in 2011, showing overall survival in the Phase 3 trial for the first time, and is currently used by MDS patients having difficulties in hematopoietic stem cell transplantation.

**About Onconova Therapeutics, Inc.**

Onconova Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit <http://www.onconova.com>.

**About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus on oncology, hematology and pain management.